Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 28;10(5):923.
doi: 10.3390/jcm10050923.

Relative Importance of Heart Failure Events Compared to Stroke and Bleeding in AF Patients

Sandro Ninni  1 , Gilles Lemesle  1 , Thibaud Meurice  2 , Olivier Tricot  3 , Nicolas Lamblin  4 , Christophe Bauters  4
Affiliations

Relative Importance of Heart Failure Events Compared to Stroke and Bleeding in AF Patients

Sandro Ninni et al. J Clin Med. .

Abstract

Introduction: Incident heart failure (HF), ischemic stroke and systemic embolism (IS/SE), and major bleeding related to anticoagulation therapy are still the most frequent events occurring in patients with atrial fibrillation (AF). The aim of this study was to assess the 3-year incidence, predictors, and related mortality of IS/SE, major bleeding, and HF in a large cohort of AF outpatients.

Methods and results: We studied 4973 outpatients with prevalent AF included in the CARDIONOR registry. The mean age was 72.9 ± 11.2 years, 24.1% had diabetes mellitus and 78.9% had anticoagulant therapy at baseline. The mean CHA2DS2Vasc score was 3.4 ± 1.7. After a median follow-up of 3.2 years (IQR: 2.8 to 3.5), incident HF, IS/SE and major bleeding occurred in 10.5%, 3.3% and 2.1% of patients, respectively. When analyzed as time-dependent variables, IS/SE, major bleeding and hospitalization for decompensated HF were all strongly associated with mortality. The independent predictors of incident HF were age, women, hypertension, diabetes mellitus, coronary artery disease and a previous history of HF. A sensitivity analysis in patients without history of HF at inclusion revealed that incident HF remained the most frequent adverse event, occurring in 5.3% of patients, compared to IS/SE (1.7%) and major bleeding (2.5%).

Conclusion: HF is a common residual cardiovascular adverse event occurring in AF outpatients and is associated with a very high mortality. Since modifiable risk factors are associated with incident HF, upstream intensive management of these risk factors would be of interest.

Keywords: atrial fibrillation; bleeding; heart failure; stroke.

PubMed Disclaimer

Conflict of interest statement

Lemesle reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Mylan, Novartis, Pfizer, Sanofi-Aventis, and Servier. Lamblin reports personal fees from Actelion, Akcea, Amicus therapeutics, Bayer, Novartis, MSD, Pfizer, and Sanofi-Aventis and travel grants from Amgen and Bristol-Myers Squibb. Ninni, Meurice, Tricot, and Bauters had nothing to disclose.

Figures

Figure 1
Figure 1
Incident events during follow-up. Cumulative incidence functions (death as the competing event) are shown. (A) Overall study population (n = 4951 with follow-up). (B) Patients without HF at inclusion (n = 3288 with follow-up). (C) Patients with HF at inclusion (n = 1663 with follow-up). HF, heart failure.
Figure 2
Figure 2
Impact of incident events on subsequent mortality during the follow-up period. Ischemic stroke/systemic embolism (IS/SE), major bleeding, and hospitalization for heart failure (HF) were analyzed as time-dependent variables. HR, hazard ratio; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Magnussen C., Niiranen T.J., Ojeda F.M., Gianfagna F., Blankenberg S., Njølstad I., Vartiainen E., Sans S., Pasterkamp G., Hughes M., et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe) Circulation. 2017;136:1588–1597. doi: 10.1161/CIRCULATIONAHA.117.028981. - DOI - PMC - PubMed
    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.-A., Dilaveris P.E., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42:373–498. - PubMed
    1. Virani Salim S., Alonso A., Aparicio Hugo J., Benjamin Emelia J., Bittencourt Marcio S., Callaway C.W., Carson A.P., Chamberlain A.M., Cheng S., Delling F.N., et al. Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association. Circulation. 2021 doi: 10.1161/CIR.0000000000000950. - DOI - PubMed
    1. Pastori D., Menichelli D., Del Sole F., Pignatelli P., Violi F., ATHERO-AF study group Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. Mayo Clin. Proc. 2020 doi: 10.1016/j.mayocp.2020.06.057. - DOI - PubMed
    1. Kotecha D., Lam C.S., Van Veldhuisen D.J., Van Gelder I.C., Voors A.A., Rienstra M. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. J. Am. Coll. Cardiol. 2016;68:2217–2228. doi: 10.1016/j.jacc.2016.08.048. - DOI - PubMed

LinkOut - more resources